Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Hypertriglyceridemia: HELP
Articles by Sang-Rok Lee
Based on 1 article published since 2010
(Why 1 article?)
||||

Between 2010 and 2020, Sang-Rok Lee wrote the following article about Hypertriglyceridemia.
 
+ Citations + Abstracts
1 Clinical Trial Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results. 2016

Yang, Xiaohong / Lee, Sang-Rok / Choi, Yun-Seok / Alexander, Veronica J / Digenio, Andres / Yang, Qingqing / Miller, Yury I / Witztum, Joseph L / Tsimikas, Sotirios. ·Division of Cardiovascular Medicine, Sulpizio Cardiovascular Center, University of California San Diego, La Jolla, CA. · Division of Cardiovascular Medicine, Sulpizio Cardiovascular Center, University of California San Diego, La Jolla, CA Division of Cardiology, Chonbuk National University Hospital and Chonbuk School of Medicine, Jeonju, Korea. · Division of Cardiovascular Medicine, Sulpizio Cardiovascular Center, University of California San Diego, La Jolla, CA Division of Cardiology, Department of Internal Medicine, College of Medicine, Catholic University of Korea, Seoul, Korea. · Ionis Pharmaceuticals, Carlsbad, CA. · Akcea Therapeutics, Cambridge, MA. · Division of Endocrinology and Metabolism, University of California San Diego, La Jolla, CA. · Division of Cardiovascular Medicine, Sulpizio Cardiovascular Center, University of California San Diego, La Jolla, CA Ionis Pharmaceuticals, Carlsbad, CA stsimikas@ucsd.edu. ·J Lipid Res · Pubmed #26848137.

ABSTRACT: Elevated apoC-III levels predict increased cardiovascular risk when present on LDL and HDL particles. We developed novel high-throughput chemiluminescent ELISAs that capture apoB, lipoprotein (a) [Lp(a)], and apoA-I in plasma and then detect apoC-III on these individual lipoproteins as apoCIII-apoB, apoCIII-Lp(a), and apoCIII-apoAI complexes, respectively. We assessed the effects on these complexes of placebo or 100-300 mg volanesorsen, a generation 2.0+ antisense drug that targets apoC3 mRNA in patients with hypertriglyceridemia, including familial chylomicronemia syndrome (n = 3), volanesorsen monotherapy (n = 51), and as add-on to fibrate (n = 26), treated for 85 days and followed for 176 days. Compared with placebo, volanesorsen was associated with an 82.3 ± 11.7%, 81.3 ± 15.7%, and 80.8 ± 13.6% reduction in apoCIII-apoB, apoCIII-Lp(a), and apoCIII-apoA-I, respectively (300 mg dose;P< 0.001 for all), at day 92. Strong correlations in all assay measures were noted with total plasma apoC-III, chylomicron-apoC-III, and VLDL-apoC-III. In conclusion, novel high-throughput ELISAs were developed to detect lipoprotein-associated apoC-III, including for the first time on Lp(a). Volanesorsen uniformly lowers apoC-III on apoB-100, Lp(a), and apoA-I lipoproteins, and may be a potent agent to reduce triglycerides and cardiovascular risk mediated by apoC-III.